Class Action Filed Against GSK plc (GSK) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Portfolio Pulse from
A class action securities lawsuit has been filed against GlaxoSmithKline (GSK) alleging securities fraud between February 2020 and August 2022. The lawsuit claims GSK misled investors about the Zantac drug's potential cancer risks and the source of NDMA contamination, suggesting the company knew about the issue for nearly 40 years before withdrawing the drug from the market.
March 21, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The class action lawsuit could negatively impact GSK's stock price by raising concerns about potential financial liability and management credibility regarding the Zantac drug controversy.
The lawsuit alleges systematic misrepresentation about Zantac's safety, which could lead to potential financial penalties, reputational damage, and investor loss of confidence.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100